Tubulin alterations in taxol-induced apoptosis parallel those observed with other drugs

C M Ireland1, S M Pittman

  • 1Children's Leukaemia and Cancer Research Centre, Prince of Wales Children's Hospital, Sydney, Australia.

Insights

Taxol treatment induces visible tubulin polymerization and structures during apoptosis in human T-cell leukemia. These tubulin changes during apoptosis are similar to those caused by other cytotoxic drugs.

Area of Science:

  • Cell Biology
  • Molecular Biology
  • Cancer Research

Background:

  • Cellular tubulin reorganizes into visible structures during apoptosis, correlating with morphological changes.
  • These tubulin structures differ from those in non-apoptotic or mitotic cells.
  • Taxol (paclitaxel) is known to enhance microtubule polymerization and stabilize tubulin structures.

Purpose of the Study:

  • To investigate the role of tubulin in taxol-induced apoptosis.
  • To characterize the tubulin structures formed during taxol-induced apoptosis in a human T-cell line (CCRF-CEM).

Main Methods:

  • Induction of apoptosis in CCRF-CEM cells using 10 nM taxol.
  • Immunocytochemical analysis using a beta-tubulin antibody.
  • DNA fragmentation assays.
  • Flow cytometry for cell cycle analysis.
  • Microscopic observation of microtubule structures.
  • Analysis of tubulin mRNA expression.

Main Results:

  • Taxol treatment induced typical apoptotic morphology and visible tubulin polymerization.
  • Cells accumulated in G2/M phase, with hypodiploid peaks appearing concurrently with DNA fragmentation.
  • Three types of microtubule structures were observed: apoptotic-associated tubulin structures, mitotic arrest with abnormal spindles, and cytoplasmic/perinuclear polymerization.
  • Tubulin mRNA levels transiently increased before DNA fragmentation across taxol, methotrexate, and etoposide treatments.

Conclusions:

  • Taxol induces tubulin polymerization and distinct structures during apoptosis in human T-cell leukemia.
  • These taxol-induced tubulin changes share similarities with apoptosis induced by drugs not directly targeting tubulin.
  • Tubulin mRNA expression increases prior to DNA fragmentation in drug-induced apoptosis, suggesting a role in the apoptotic process.

Related Concept Videos

Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...